Which Treatment Suits Your Weight Management Goals?
Wegovy V Mounjaro UK: Understanding Your In-Stock Options
The decision between Wegovy v Mounjaro UK no longer needs to be delayed by availability concerns. At EverydayMeds, we maintain comprehensive stock levels of both treatments, recognising that consistent access is crucial for successful weight management. Wegovy (semaglutide) operates as a GLP-1 receptor agonist, whilst Mounjaro (tirzepatide) functions as a dual GIP and GLP-1 receptor agonist. Both prescription-only medicines require clinical assessment, but our streamlined process means you can access either treatment within days rather than months.
Supply chain reliability has been a significant concern for patients considering these treatments, particularly with Wegovy's historical availability challenges. Our partnership with Novo Nordisk ensures consistent Wegovy stock across all five doses, whilst our Mounjaro inventory covers the complete tirzepatide range. This dual availability means your prescriber can recommend the most suitable option based on your medical history and weight management goals, knowing both treatments are immediately accessible through our GPhC-registered service (#9012878).
Wegovy V Mounjaro UK Pricing: Complete Cost Breakdown
Understanding the financial commitment for Wegovy v Mounjaro UK helps inform your treatment decision. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our bundle options provide convenience for multi-month planning: the Intro Duo (0.25mg & 0.5mg) costs £169.99, whilst the Ultimate Stability Trio offers three months of 2.4mg maintenance for £649.99. New customers apply code FIRST40 at checkout, with returning customers using DOSE25.
Mounjaro follows a different pricing structure reflecting its dual-hormone mechanism, with costs varying based on the specific tirzepatide dose prescribed. Both treatments require gradual dose escalation over 16-20 weeks, making our bundle packages particularly valuable for ensuring treatment continuity. The investment in either Wegovy or Mounjaro represents a comprehensive weight management approach that extends beyond the medication itself, incorporating dietary guidance and lifestyle modifications as mandated by MHRA licensing requirements.
Clinical Evidence: Wegovy V Mounjaro UK Trial Data
The STEP clinical trial programme demonstrates Wegovy's efficacy in weight management applications. STEP 1 showed participants achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo, whilst STEP 5 demonstrated sustained 15.2% weight reduction at two years. The SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events, highlighting benefits beyond weight management.
Mounjaro's clinical evidence comes from the SURMOUNT trial series, showing significant weight management outcomes in participants using tirzepatide alongside lifestyle interventions. Comparing Wegovy v Mounjaro UK trial results directly isn't appropriate due to different study populations, endpoints, and methodologies, but both demonstrate substantial efficacy when used as prescribed alongside a reduced-calorie diet and increased physical activity.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of glucagon-like peptide-1, a natural hormone released after eating. This mechanism reduces appetite by acting on brain centres that control hunger and satiety, helping patients feel fuller after smaller meals. The medication slows gastric emptying, meaning food remains in the stomach longer, contributing to prolonged feelings of satisfaction. Semaglutide may also reduce food cravings and the psychological drive to eat, particularly for high-calorie foods. The once-weekly injection maintains consistent hormone levels, providing steady appetite control throughout the week. This biological approach to weight management works alongside dietary changes and increased physical activity to support sustainable weight reduction.
Ordering Process: From Assessment to Delivery
Accessing either option in our Wegovy v Mounjaro UK comparison begins with a comprehensive 3-minute online clinical assessment covering medical history, current medications, and weight management goals. Our qualified prescribers review applications within 24-48 hours (express review available), ensuring appropriate treatment selection based on individual circumstances. Upon approval, medications are dispatched via next-day delivery using specialised cold-chain packaging to maintain the 2-8°C temperature requirements. Our courier service provides tracking information and requires signature upon delivery to ensure secure receipt. The entire process from assessment to receiving your medication typically takes 2-4 working days, significantly faster than traditional GP referral pathways.
Storage and Practical Considerations
Storage requirements differ between these treatments, with Wegovy offering superior temperature flexibility for UK lifestyles. Both medications require refrigerated storage at 2-8°C, but Wegovy can remain at room temperature (below 30°C) for up to 6 weeks once removed from the fridge, compared to Mounjaro's 21-day limit. The FlexTouch pen system used for Wegovy provides intuitive dose administration with clear dosing windows and automatic needle insertion. Dose escalation protocols are mandatory for both treatments, starting with the lowest strength and gradually increasing every 4 weeks to minimise gastrointestinal side effects. Both medications are administered once weekly, preferably on the same day each week, with injection sites rotated between thigh, abdomen, or upper arm. Travel convenience favours Wegovy due to its extended room temperature stability, particularly important for UK patients with active lifestyles.
Supply Chain Reliability: Why Stock Availability Matters for Wegovy V Mounjaro UK
Consistent medication access directly impacts treatment success, making our reliable Wegovy v Mounjaro UK inventory crucial for patient outcomes. Weight management medications require continuous use for optimal effectiveness, with treatment interruptions potentially compromising progress and requiring dose re-escalation. Our robust supply relationships with both Novo Nordisk and Eli Lilly ensure we can fulfill orders without the delays that have historically affected these treatments.
Stock forecasting incorporates seasonal demand patterns, dose escalation requirements, and maintenance therapy needs to prevent shortages. Patients can confidently begin treatment knowing their subsequent doses will be available when needed, eliminating the anxiety associated with uncertain medication access. This reliability allows focus on the lifestyle changes essential for successful weight management rather than worrying about treatment continuity.
Making Your Decision: Wegovy V Mounjaro UK Treatment Selection
Choosing between Wegovy v Mounjaro UK involves considering multiple factors beyond simple availability, though our comprehensive stock eliminates that concern. Your prescriber will evaluate your medical history, concurrent medications, previous weight management attempts, and specific health goals to recommend the most appropriate option. Both treatments require commitment to dietary modification and increased physical activity as specified in their MHRA licensing conditions. The decision may also factor in practical considerations such as injection frequency preferences, storage requirements, and cost considerations over the complete treatment duration. Neither treatment should be considered superior without individual clinical context, as both offer proven efficacy for appropriate candidates. Our experienced prescribers can guide this decision during the clinical assessment, ensuring you receive the treatment most likely to support your weight management success alongside the comprehensive lifestyle modifications essential for optimal outcomes.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
